You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Lilly Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Lilly
International Patents:30
US Patents:1
Tradenames:85
Ingredients:81
NDAs:105

Drugs and US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-005 Nov 26, 2002 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Lilly DYMELOR acetohexamide TABLET;ORAL 013378-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Lilly KEFUROX IN PLASTIC CONTAINER cefuroxime sodium INJECTABLE;INJECTION 062590-002 Jan 10, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Lilly DIETHYLSTILBESTROL diethylstilbestrol TABLET;ORAL 004041-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lilly

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-006 Nov 26, 2002 5,658,590*PED ⤷  Sign Up
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984 4,619,935 ⤷  Sign Up
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 5,658,590*PED ⤷  Sign Up
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 4,418,068 ⤷  Sign Up
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 5,747,510 ⤷  Sign Up
Lilly PROZAC fluoxetine hydrochloride SOLUTION;ORAL 020101-001 Apr 24, 1991 4,314,081*PED ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 2008-07-01
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 2012-06-27
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 2015-07-27
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 2007-11-21
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 2012-05-10
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 2005-01-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2005-11-01
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 2007-08-24
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-02-04
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 2016-10-06
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2008-10-14
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 2008-08-04
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 2008-05-08
➤ Subscribe For Injection 1g/vial ➤ Subscribe 2005-11-14

Supplementary Protection Certificates for Lilly Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 13C0055 France ⤷  Sign Up PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2957286 C02957286/01 Switzerland ⤷  Sign Up PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66411 22.12.2017
0584952 SPC/GB98/048 United Kingdom ⤷  Sign Up PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805
2782584 LUC00245 Luxembourg ⤷  Sign Up PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701
1539166 2013/055 Ireland ⤷  Sign Up PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
2101777 122016000039 Germany ⤷  Sign Up PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.